In vivo models / in vitro models / knock-out / knock-in / CRISPR/Cas9 / humanized / mouse model / rat model / Transgenic / disease models / target validation

genOway has developed a unique platform of preclinical models for profiling of immune targeting agents in Immuno-Oncology and Immuno-Inflammation. These models enable the evaluation of biologics in a context of well-calibrated syngeneic tumors (h- VISTA, hPD-1, hCTLA-4, hCD28, hGITR, h4-1BB, hTIM-3/hPD-1, etc.) or the use of Xenograft tumors (Human Immune System mice). All models are provided with the necessary freedom to operate: genOway holds exclusive IP on key technologies, such as the knock-in and the CRISPR/Cas9. Moreover, genOway offers access to 2000 models of target validation and compound specificity assessment. After 20 years of interaction with 17 of the top 20 pharmaceutical companies and numerous renowned biotech companies, genOway has gathered a tremendous experience in preclinical model development